Climacteric
Conditions
Interventions
This study was prospective, double-blind, randomized, developed between September 2018 to January 2020. The patients were selected at the climacteric outpatient clinic of the Endocrine and Climacteric
Drug
Sponsors
Universidade Federal de São Paulo
Universidade Federal de São Paulo
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Spontaneous menopause in the last 5 years; any age; denial of the use of hormone therapy in the last 12 months.
Exclusion criteria
Exclusion criteria: History of previous or present malignant disease; previous or present endometrial hyperplasia and an outdated gynecological routine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of genitourinary symptoms after menopause after the use of topical vaginal oxytocin, verified through a questionnaire answered by patients before medication, 45 days after and 3 months after, symptoms including vaginal dryness, pain or discomfort during sexual intercourse and urinary frequency. Improvement in the thickness of the vaginal epithelium after the use of topical vaginal oxytocin, epithelial thickness measured by a pathologist in the thickest site using a Reticulum Melanoma ruler (Breslow's Ruler). | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of the gynecological examination after the use of vaginal oxytocin, verified through the evaluation of the gynecologist researcher, including the parameters of vaginal color, roughness, petechiae and friability. | — |
Countries
Brazil
Contacts
Public ContactLiani Andrade Santos
Universidade Federal de São Paulo
Outcome results
None listed